Biocon Biologics Receives Complete Response Letter from US FDA for Biosimilar Insulin Aspart

  • Posted by: Biocon Biologics

Biocon Biologics Receives European Commission Approval for YESAFILI®, Biosimilar Aflibercept

  • Posted by: Biocon Biologics

Biocon Board Appoints Peter Bains as Group CEO

  • Posted by: Biocon Biologics

Biocon Biologics Continues to Expand Global Footprint, Completes Integration of Viatris Biosimilars’ Business In North America, Ahead of Schedule

  • Posted by: Biocon Biologics

Biocon Q1FY24 Revenue at Rs 3,516 Cr, Up 59%; Biosimilars Up 106%; Research Services Up 25%

  • Posted by: Biocon Biologics

Biocon Biologics Announces Key Leadership Appointments

  • Posted by: Biocon Biologics

Biocon Biologics Announces Positive CHMP Opinion for YESAFILI®, Biosimilar Aflibercept

  • Posted by: Biocon Biologics

U.S. FDA Completes Two cGMP Inspections at Biocon Biologics Insulins Facility in Malaysia

  • Posted by: Biocon Biologics

Biocon Biologics Expands Footprint in Emerging Markets Takes Over the Commercialization of Biosimilars Business from Viatris in 70+ countries

  • Posted by: Biocon Biologics

After Five Years of Successful Experience Internationally, Biocon Biologics’ Hulio® Biosimilar to Humira®, Now Available in the United States

Hulio bAdalimumab
  • Posted by: Biocon Biologics
Share